BCRX · Quarterly Report (Form 10-Q) · Filed August 5, 2025

Biocryst Pharmaceuticals Inc — 10-Q exhibit

bcrx-20250630x10xqxex102.htm

Biocryst Pharmaceuticals Inc on Boardroom Alpha

Document

Exhibit 10.2

AMENDMENT TO CONSULTING AGREEMENT

THIS FIRST AMENDMENT to the CONSULTING AGREEMENT (the “First Amendment”) is made and entered into on this 31st day of May, 2025 (the “First Amendment Effective Date”), by and between BioCryst Pharmaceuticals, Inc., a Delaware Corporation and Anthony Doyle

RECITALS

WHEREAS, BioCryst and Anthony Doyle entered into a Consulting Agreement (the “Agreement”) having an effective date of April 9, 2025; and

WHEREAS, both parties wish to extend the term of the Agreement.

NOW, THEREFORE, in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, BioCryst and Anthony Doyle, intending to be legally bound, have agreed to amend the terms of the Agreement as follows:

The Term of the Agreement shall be extended through December 31, 2025, and shall automatically continue thereafter on a month-to-month basis until terminated by either party upon thirty (30) days’ written notice.

Except as expressly amended hereby, the Agreement shall remain in full force and effect in accordance with its terms.

IN WITNESS WHEREOF, the parties have executed this Amendment as of the first date above written.


Anthony Doyle			BioCryst Pharmaceuticals, Inc.
Signature: /s/ Anthony Doyle			Signature: /s/ Alane Barnes
Name: Anthony Doyle			Name: Alane Barnes
Title: Consultant			Title: Chief Legal Officer

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer